• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » St. Jude Medical beats The Street, lowers guidance

St. Jude Medical beats The Street, lowers guidance

October 19, 2011 By MassDevice staff

St. Jude Medical

St. Jude Medical (NYSE:STJ) beat Wall Street’s forecasts for its third-quarter sales and earnings, sending its shares up nearly 5 percent in early-morning trading despite a lower forecast for full-year earnings.

Profits were up 8.7 percent and sales rose 11.5 percent for the St. Paul, Minn.-based medical device maker, which posted earnings of $226.5 million, or 69 cents per diluted share, on sales of $1.38 billion during the three months ended Oct. 1. That compares with profits of $208.4 million, or 63 cents diluted EPS, on sales of $1.24 billion during the same period last year.

St. Jude’s adjusted EPS was 78 cents per share, excluding charges of $20.9 million (6 cents per share) "primarily related to ongoing restructuring actions that began in the second quarter to realign certain activities in our CRM business as well as employee termination and other costs primarily associated with continuing efforts to improve our international sales & sales support organization," according to a press release, and another $8.5 million (3 cents per share) "related to increased collection risk for accounts receivable related to one customer in Europe." Analysts had expected adjusted EPS of 76 cents per share and St. Jude’s own forecast was for 74 cents to 76 cents.

Sign up to get our free newsletters delivered right to your inbox

But the company cut its prediction for full-year adjusted earnings from $3.25 to $3.30 down to between $3.26 and $3.28 per share; The Street has its hopes pegged on adjusted EPS of $3.27 per share.

Sales of implantable cardiac defibrillators and pacemakers were up 2 percent to $751 million, with ICD sales up 1 percent to $445 million and pacemaker sales up 2 percent to $306 million. Atrial fibrillation sales rose 20 percent to $202 million; neuromodulation sales rose 10 percent to $102 million. Vascular and structural heart product sales were $328 million, up 37 percent including revenues from AGA Medical Inc., which St. Jude bought last year for $1.03 billion.

Sales of vascular products in the third quarter of 2011 were $177 million, up 10 percent from the comparable quarter in 2010.

Structural heart product sales for the third quarter of 2011 were $151 million, a 91 percent increase over the third quarter of 2010, with the addition of AGA Medical products to the business.

STJ shares were up nearly 4.5 percent to $39 as of about 10:15 this morning.

Filed Under: MassDevice Earnings Roundup, News Well, Wall Street Beat Tagged With: Q3, stjudemedical

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy